Research Funding

  • January 1, 2021 - November 30, 2025 - Structural and Functional Studies of HER Receptors , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R35GM139636
  • April 1, 2019 - March 31, 2024 - The structural and functional basis of MET exon 14 activation and acquired drug resistance , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01CA230263
  • September 1, 2020 - August 31, 2021 - Structural and functional investigation of the understudied HIPK1 kinase , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R03TR003400
  • September 1, 2014 - August 31, 2020 - Structural and Functional Studies of HER Receptor Tyrosine Kinases , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01GM109176
  • July 6, 2018 - July 5, 2019 - FASEB SRC Protein Phosphorylation Networks in Health and Disease , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R13CA232438

Education

  • Jagiellonian University, Krakow, Poland, M.S., 2001, Molecular Biology
  • State University of New York at Stony Brook, Ph.D., 2006, Molecular and Cellular Biology
  • University of California, Berkeley, Postdoctoral, 2010, Structural and Molecular Biology

Honors & Awards

  • 2021
    Byers Award in Basic Science, Sandler Foundation
  • 2020
    ASBMB Women in Biochemistry and Molecular Biology Leadership Award
  • 2019
    Bold and Basic Award in Psychiatric Disease
  • 2019
    PBBR/New Frontier Research Award
  • 2018
    PBBR/New Frontier Research Award
  • 2018
    Deleage Foundation Award
  • 2015
    Susan G Komen Career Award
  • 2015
    Lung Cancer Foundation Research Award
  • 2004
    AACR-Pfizer Scholar-in-Training Award
  • 2003
    Sigma Xi Award for Excellence in Travel

Selected Publications

  1. Estevam GO, Linossi EM, Macdonald CB, Espinoza CA, Michaud JM, Coyote-Maestas W, Collisson EA, Jura N, Fraser JS. Conserved regulatory motifs in the juxtamembrane domain and kinase N-lobe revealed through deep mutational scanning of the MET receptor tyrosine kinase domain. bioRxiv. 2023 Aug 03.  View on PubMed
  2. Daggubati V, Vykunta A, Choudhury A, Qadeer Z, Mirchia K, Saulnier O, Zakimi N, Hines K, Paul M, Wang L, Jura N, Xu L, Reiter J, Taylor M, Weiss W, Raleigh D. Hedgehog target genes regulate lipid metabolism to drive basal cell carcinoma and medulloblastoma. Res Sq. 2023 Aug 03.  View on PubMed
  3. Torosyan H, Paul MD, Forget A, Lo M, Diwanji D, Pawlowski K, Krogan NJ, Jura N, Verba KA. Structural insights into regulation of the PEAK3 pseudokinase scaffold by 14-3-3. Nat Commun. 2023 06 19; 14(1):3543.  View on PubMed
  4. Santana FR, Linossi EM, Jura N. Trapping Tribbles: Nanobody-assisted structure of the TRIB2 pseudokinase. Structure. 2022 11 03; 30(11):1465-1467.  View on PubMed
  5. Campbell MR, Ruiz-Saenz A, Zhang Y, Peterson E, Steri V, Oeffinger J, Sampang M, Jura N, Moasser MM. Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling. Cell Rep. 2022 Sep 06; 40(10):111338.  View on PubMed
  6. Natalia Jura. Structural basis for signaling by the HER3 pseudokinase receptor. The FASEB Journal. 2022 May 13; 36(S1).  View on PubMed
  7. Lo M, Sharir A, Paul MD, Torosyan H, Agnew C, Li A, Neben C, Marangoni P, Xu L, Raleigh DR, Jura N, Klein OD. CNPY4 inhibits the Hedgehog pathway by modulating membrane sterol lipids. Nat Commun. 2022 05 03; 13(1):2407.  View on PubMed
  8. Trenker R, Diwanji D, Verba KA, Jura N. An effective strategy for ligand-mediated pulldown of the HER2/HER3/NRG1β heterocomplex and cryo-EM structure determination at low sample concentrations. Methods Enzymol. 2022; 667:633-662.  View on PubMed
  9. Diwanji D, Trenker R, Jura N, Verba KA. Efficient expression, purification, and visualization by cryo-EM of unliganded near full-length HER3. Methods Enzymol. 2022; 667:611-632.  View on PubMed
  10. Thorne LG, Bouhaddou M, Reuschl AK, Zuliani-Alvarez L, Polacco B, Pelin A, Batra J, Whelan MVX, Hosmillo M, Fossati A, Ragazzini R, Jungreis I, Ummadi M, Rojc A, Turner J, Bischof ML, Obernier K, Braberg H, Soucheray M, Richards A, Chen KH, Harjai B, Memon D, Hiatt J, Rosales R, McGovern BL, Jahun A, Fabius JM, White K, Goodfellow IG, Takeuchi Y, Bonfanti P, Shokat K, Jura N, Verba K, Noursadeghi M, Beltrao P, Kellis M, Swaney DL, García-Sastre A, Jolly C, Towers GJ, Krogan NJ. Publisher Correction: Evolution of enhanced innate immune evasion by SARS-CoV-2. Nature. 2022 Apr; 604(7905):E14.  View on PubMed
  11. Paul MD, Torosyan H, Jura N. Piquing our interest: Insights into the role of PEAK3 in signaling and disease. Sci Signal. 2022 02 22; 15(722):eabm9396.  View on PubMed
  12. Diwanji D, Trenker R, Thaker TM, Wang F, Agard DA, Verba KA, Jura N. Author Correction: Structures of the HER2-HER3-NRG1β complex reveal a dynamic dimer interface. Nature. 2022 Feb; 602(7898):E26.  View on PubMed
  13. Devan C. Diwanji, Raphael Trenker, Tarjani M. Thaker, Feng Wang, David A. Agard, Kliment A. Verba, Natalia Jura. Cryo-EM structures of the near full-length HER2/HER3 heterodimer reveal a novel allosteric mechanism of activation. Biophysical Journal. 2022 Feb 1; 121(3):84a.  View on PubMed
  14. Campbell MR, Ruiz-Saenz A, Zhang Y, Peterson E, Steri V, Oeffinger J, Sampang M, Jura N, Moasser MM. Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling. Cell Rep. 2022 02 01; 38(5):110285.  View on PubMed
  15. Campbell MR, Ruiz-Saenz A, Peterson E, Agnew C, Ayaz P, Garfinkle S, Littlefield P, Steri V, Oeffinger J, Sampang M, Shan Y, Shaw DE, Jura N, Moasser MM. Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers. Cell Rep. 2022 02 01; 38(5):110291.  View on PubMed
  16. Jura N, Murphy JM. Preface. Methods Enzymol. 2022; 667:xxi-xxiv.  View on PubMed
  17. Thorne LG, Bouhaddou M, Reuschl AK, Zuliani-Alvarez L, Polacco B, Pelin A, Batra J, Whelan MVX, Hosmillo M, Fossati A, Ragazzini R, Jungreis I, Ummadi M, Rojc A, Turner J, Bischof ML, Obernier K, Braberg H, Soucheray M, Richards A, Chen KH, Harjai B, Memon D, Hiatt J, Rosales R, McGovern BL, Jahun A, Fabius JM, White K, Goodfellow IG, Takeuchi Y, Bonfanti P, Shokat K, Jura N, Verba K, Noursadeghi M, Beltrao P, Kellis M, Swaney DL, García-Sastre A, Jolly C, Towers GJ, Krogan NJ. Evolution of enhanced innate immune evasion by SARS-CoV-2. Nature. 2022 02; 602(7897):487-495.  View on PubMed
  18. Jin N, Keam B, Cho J, Lee MJ, Kim HR, Torosyan H, Jura N, Ng PK, Mills GB, Li H, Zeng Y, Barbash Z, Tarcic G, Kang H, Bauman JE, Kim MO, VanLandingham NK, Swaney DL, Krogan NJ, Johnson DE, Grandis JR. Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma. J Clin Invest. 2021 11 15; 131(22).  View on PubMed
  19. Diwanji D, Trenker R, Thaker TM, Wang F, Agard DA, Verba KA, Jura N. Structures of the HER2-HER3-NRG1β complex reveal a dynamic dimer interface. Nature. 2021 12; 600(7888):339-343.  View on PubMed
  20. Swaney DL, Ramms DJ, Wang Z, Park J, Goto Y, Soucheray M, Bhola N, Kim K, Zheng F, Zeng Y, McGregor M, Herrington KA, O'Keefe R, Jin N, VanLandingham NK, Foussard H, Von Dollen J, Bouhaddou M, Jimenez-Morales D, Obernier K, Kreisberg JF, Kim M, Johnson DE, Jura N, Grandis JR, Gutkind JS, Ideker T, Krogan NJ. A protein network map of head and neck cancer reveals PIK3CA mutant drug sensitivity. Science. 2021 Oct; 374(6563):eabf2911.  View on PubMed

Go to UCSF Profiles, powered by CTSI